Category Archives: Biotechnology

Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May30, 2017 (May 24, 2017) PUMA BIOTECHNOLOGY, INC. (Exact Name of Registrant as Specified in its Charter) 10880 Wilshire Boulevard, Suite 2150 Los Angeles, California 90024 (Address of principal executive offices) (Zip Code) (424) 248-6500 (Registrants telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided … Continue reading →

FactsReporter Puma Biotechnology (PBYI) Receives Media Impact Rating of -0.13 The Cerbat Gem Puma Biotechnology logo Media stories about Puma Biotechnology (NYSE:PBYI) have trended somewhat negative recently, Alpha One Sentiment reports. The research firm, a subsidiary of Accern, ranks the sentiment of news coverage by reviewing more ... Brokerages Set Puma Biotechnology Inc (PBYI) Target Price at $68.42BBNS Is Puma Biotechnology, Inc. (PBYI) a good buy?TopChronicle Puma Biotechnology, Inc. (NYSE:PBYI) Stock Sees The Needle Move 110.98%Concord Register FactsReporter -Transcript Daily -Post Analyst -Zacks Investment Research all 87 news articles » Continue reading here: Puma Biotechnology (PBYI) Receives Media Impact Rating of -0.13 - The Cerbat Gem … Continue reading →

Wednesday was a good day for stocks, and the Dow Jones Industrials and S&P 500 both climbed through milestone levels. Most market participants attributed the positive sentiment to the Federal Reserve, which released the minutes of its latest monetary policy meeting during the afternoon. The central bank revealed plans to clamp down on the size of its balance sheet, which it initially expanded in the aftermath of the financial crisis to provide liquidity to the bond market and additional stimulus to the U.S. economy. Investors were pleased that the Fed believes that it's no longer necessary to extend that level of monetary accommodation to the economy. In addition, some individual companies had extremely good news, and Abercrombie & Fitch (NYSE:ANF), Triumph Group (NYSE:TGI), and Puma Biotechnology (NASDAQ:PBYI) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well. Shares of Abercrombie & Fitch climbed 6% in the wake of reports that the teen retailer might receive an acquisition bid from a consortium of investors. According to The Wall Street Journal(subscription required), industry peer American Eagle Outfitters (NYSE:AEO) and private equity company Cerberus Capital Management are looking at … Continue reading →

Thanks to a $40,320 grant from the Ohio Department of Higher Education, some hard-working Lakeland Community College biotechnology students will be eligible for scholarships to cover their tuition and fees. The program is called Choose Ohio First and is aimed at helping students pursuing degrees in science, technology, engineering, mathematics and medicine or STEMM, its associated web page shows. In Lakelands case, the grant applies to biotechnology science students who meet certain criteria, a media release from the school confirms. Students who receive this scholarship will have their tuition fully covered at Lakeland, said Joe Deak, chairman of the schools biotechnology science program. Advertisement He added that two Lakeland Community College students are now using this funding. The scholarship covers up to $4,000 in tuition and fees for biotechnology students who dont receive PELL grants, according to Lakelands release. It goes on to explain that high school graduates who passed chemistry with a C or better are encouraged to apply if they fit the following criteria: Have an interest in a career in the laboratory biological sciences or data/analysis management as it pertains to biological data Have a 3.0 overall GPA Place into college algebra Reside in Ohio. Lakelands recent … Continue reading →

Share Price and 1 Year Extreme Prices Analysis The share of Puma Biotechnology, Inc. (PBYI) currently has a value of $78.05 while the companys 52 week low is at $27.64, the shares dropped to the 52 week low on 06/27/16. While the companys share hit the 52 week high on 05/25/17 stationing the value of $75.10. The difference of 52 week low value as well as 52 week high value and the current price of the stock suggests the next move of the shares. If the share price is currently hovering near the 52 week low and the value is achieved in the current past then it can suggest that the price of the shares is likely to go up. Share Volume Analysis The volume of the particular stock is the shares bought and sold in a single trading day. The average volume of a stock suggests the liquidity of a particular company. If the average volume is low then the liquidity is low which means it is hard to buy or sell the stock as there are fewer buyers or sellers of the stock. Currently the shares of Puma Biotechnology, Inc. (PBYI) has the trading volume of 5.7 Million … Continue reading →

NY Stock News The Bears And Bulls Square Off On Puma Biotechnology, Inc. (PBYI) NY Stock News Puma Biotechnology, Inc. (PBYI) has presented a rich pool of technical data in recent sessions. These are the trends we've been tracking and how we feel they should be played in the current environment. Successful trading professionals know that in ... Abercrombie & Fitch Company - ANF - Stock Price Today - ZacksZacks all 68 news articles » Read the original here: The Bears And Bulls Square Off On Puma Biotechnology, Inc. (PBYI) - NY Stock News … Continue reading →

Transcript Daily iShares NASDAQ Biotechnology Index (IBB) Position Boosted by Gerber Kawasaki Wealth & Investment Management The Cerbat Gem iShares NASDAQ Biotechnology Index logo Gerber Kawasaki Wealth & Investment Management increased its stake in shares of iShares NASDAQ Biotechnology Index (NASDAQ:IBB) by 47.3% during the first quarter, according to its most recent Form 13F ... iShares NASDAQ Biotechnology Index (IBB) Shares Bought by Mycio Wealth Partners LLCSports Perspectives iShares NASDAQ Biotechnology Index (IBB) Stake Reduced by Bartlett & Co. LLCBBNS Caldwell & Orkin Inc. Takes Position in iShares NASDAQ Biotechnology Index (IBB)Chaffey Breeze Markets Daily -Transcript Daily all 22 news articles » See the original post: iShares NASDAQ Biotechnology Index (IBB) Position Boosted by Gerber Kawasaki Wealth & Investment Management - The Cerbat Gem … Continue reading →

Forbes Puma Biotechnology FDA Live Blog Forbes This is a live blog of the meeting of the Food and Drug Administration's meeting regarding neratinib, a breast cancer drug being developed by Puma Biotechnology. The basic questions to be addressed, per my story from Monday. Puma's not applying to sell ... Why Puma Biotechnology Inc Jumped Higher TodayMotley Fool Puma Biotechnology (PBYI) Jumps: Stock Adds 29.7% in SessionZacks.com Drilling Down Into Puma Biotechnology, Inc. (PBYI)StockNewsJournal Business Wire (press release) -Seeking Alpha -Smarter Analyst -Zacks all 124 news articles » See the original post here: Puma Biotechnology FDA Live Blog - Forbes … Continue reading →

Wednesday was a good day for stocks, and the Dow Jones Industrials and S&P 500 both climbed through milestone levels. Most market participants attributed the positive sentiment to the Federal Reserve, which released the minutes of its latest monetary policy meeting during the afternoon. The central bank revealed plans to clamp down on the size of its balance sheet, which it initially expanded in the aftermath of the financial crisis to provide liquidity to the bond market and additional stimulus to the U.S. economy. Investors were pleased that the Fed believes that it's no longer necessary to extend that level of monetary accommodation to the economy. In addition, some individual companies had extremely good news, and Abercrombie & Fitch (NYSE: ANF), Triumph Group (NYSE: TGI), and Puma Biotechnology (NASDAQ: PBYI) were among the best performers on the day. Below, we'll look more closely at these stocks to tell you why they did so well. Shares of Abercrombie & Fitch climbed 6% in the wake of reports that the teen retailer might receive an acquisition bid from a consortium of investors. According to The Wall Street Journal(subscription required), industry peer American Eagle Outfitters (NYSE: AEO) and private equity company Cerberus Capital … Continue reading →

Amicus Therapeutics (NASDAQ:FOLD) is a global biotherapeutics company focused on rare genetic devastating diseases. The company has advanced its precision medicine, Galafold (migalastat), in treating patients in Europe with Fabry disease (alpha galactosidase A deficiency), a rare X-linked genetic lysosomal disorder in which sphingolipids are not metabolized properly. Galafold, an orally administered drug, is the first medicine approved (EMA but not yet FDA) for treatment of Fabry disease. Other goals for 2017 include submitting a J-NDA (Japan) for migalastat, establishing a clinical plan for ATB200/AT2221 in Pompe disease, completion of phase 3 clinical trial in epidermolysis bullosa. FOLD announced its regulatory plan with FDA for U.S. treatment with Galafold in advancing it's Fabry disease program including two phase 3 trials in late 2016. As previously mentioned, the EMA approved use of Galafold for treatment of Fabry disease. The company published data from its pivotal trial in the New England Journal of Medicine. A statistically significant benefit was conferred by Galafold in 50 patients with treatable mutant galactosidase alleles. However, a closer look at the trial endpoints reveals that the study failed to reach its primary endpoints including greater than 50% reduction in GL-3 inclusions per kidney, and if all 67 … Continue reading →